Abrams Capital Management Portfolio Concentration Analysis: Top Holdings Overview
Abrams Capital Management's portfolio, valued at $4.64 billion as of March 31, 2026, shows significant concentration in Alphabet Inc. (GOOGL) and Somnigroup International Inc. (TPX), with notable decreases in shares for these and other holdings.

As of March 31, 2026, the portfolio managed by David Abrams, through Abrams Capital Management, stands at a total value of $4.64 billion. This analysis focuses on the top holdings within this portfolio, highlighting their significant allocations and recent changes in share count.
The largest position by allocation is Alphabet Inc. (GOOGL), commonly known as Google. This investment, representing approximately 11.57% of the total portfolio value, saw a decrease in the number of shares held by the investor during the prior period. The share reduction was -50,862 shares, reflecting a slight decrease in exposure to this major technology company.
Second on the list by allocation is Somnigroup International Inc. (TPX). This Consumer Cyclical stock accounts for about 9.24% of the portfolio. Similar to Alphabet, the investor reduced their position in Somnigroup, decreasing the share count by -5,360 shares, indicating a very minor reduction in this holding.
The third largest holding by allocation is Nuvation Bio Inc. (NUVB), a company in the Healthcare sector. This position represents a much smaller allocation of just 0.12% of the portfolio. However, it experienced the most significant change, with the investor reducing their shares by -2,541,009, leading to a drastic -66.67% change in the percentage terms. This indicates a substantial reduction or complete unwinding of this position.
For more detailed information about David Abrams and Abrams Capital Management's investment activities, please visit their profile on Insiderset: Abrams Capital Management Investor Profile. You can also explore the individual stocks in their portfolio, such as Alphabet Inc. (GOOGL), Somnigroup International Inc. (TPX), and Nuvation Bio Inc. (NUVB), on Insiderset.